These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21853589)

  • 21. The development of preferred provider organizations and its antitrust implications.
    Maram BS
    J Med Pract Manage; 1985 Oct; 1(2):130-5. PubMed ID: 10281825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitrust laws and the business of insurance.
    Berrey BH
    Va Med Q; 1993; 120(2):95-7. PubMed ID: 8481419
    [No Abstract]   [Full Text] [Related]  

  • 23. What can be done to counteract growing power of providers? Three health plans outline steps they are taking to deal with the effects of growing consolidation of providers.
    Burns J
    Manag Care; 2011 Jul; 20(7):14-6, 19-21. PubMed ID: 21848195
    [No Abstract]   [Full Text] [Related]  

  • 24. State regulation of medical discount programs: a new frontier.
    Rich JP
    Manag Care Q; 2006; 14(1):1-9. PubMed ID: 17590969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitrust implications of peer review of fees.
    Jones KB
    Pa Med; 1982 Nov; 85(11):18. PubMed ID: 6891042
    [No Abstract]   [Full Text] [Related]  

  • 26. A competitive analysis of most favored nations clauses in contracts between health care providers and insurers.
    Celnicker A
    Spec Law Dig Health Care (Mon); 1991 Dec; (154):7-36. PubMed ID: 10115476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What level of scrutiny is required in an antitrust case? 2.
    Sfikas P
    J Am Dent Assoc; 1999 Apr; 130(4):581-3. PubMed ID: 10203912
    [No Abstract]   [Full Text] [Related]  

  • 28. Say uncle. FTC fights to control hospital mergers.
    Neil R
    Mater Manag Health Care; 2003 Apr; 12(4):16-9. PubMed ID: 12854202
    [No Abstract]   [Full Text] [Related]  

  • 29. Government agencies soften stance on what constitutes price fixing.
    Ettinger DA; Lasser ML
    Healthc Financ Manage; 1997 Feb; 51(2):27-9. PubMed ID: 10164872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Judicial opportunities and limitations of Integrated Health Care in cardiology].
    Schramm F
    Clin Res Cardiol; 2006 Jan; 95 Suppl 2():II32-34. PubMed ID: 16598569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The darker side of networking--price-fixing.
    Ray HB
    J Tenn Med Assoc; 1993 Sep; 86(9):407-9. PubMed ID: 8231196
    [No Abstract]   [Full Text] [Related]  

  • 32. Most-favored-nation clauses and monopsonistic power: an unhealthy mix?
    Stenger SE
    Am J Law Med; 1989; 15(1):111-28. PubMed ID: 2764011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physicians and PPOs: antitrust considerations in setting fees.
    Fried JM; Romansky MA
    Internist; 1984 Apr; 25(4):18, 32. PubMed ID: 10266538
    [No Abstract]   [Full Text] [Related]  

  • 34. PPOs and the antitrust laws.
    Stromberg RE; Duncheon MA; Goldman JS
    Hospitals; 1983 Oct; 57(20):65-70. PubMed ID: 6618473
    [No Abstract]   [Full Text] [Related]  

  • 35. The antitrust perspective on health industry competition.
    Miller FH
    J Health Hum Resour Adm; 1989; 12(1):128-48. PubMed ID: 10296433
    [No Abstract]   [Full Text] [Related]  

  • 36. The sleeping giant awakens: the physician and the antitrust laws.
    Hirsh HL
    Leg Med; 1985; ():334-56. PubMed ID: 3835424
    [No Abstract]   [Full Text] [Related]  

  • 37. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
    Whitener MD
    Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
    [No Abstract]   [Full Text] [Related]  

  • 38. An antitrust primer for physicians.
    Anders GT; Beck LC; Bak BB; Gallagher JW
    Conn Med; 1985 Feb; 49(2):120-2. PubMed ID: 3971716
    [No Abstract]   [Full Text] [Related]  

  • 39. Competitors share contracts.
    Lovern E
    Mod Healthc; 2001 Jan; 31(3):4-5, 10. PubMed ID: 11418946
    [No Abstract]   [Full Text] [Related]  

  • 40. Price-fixing probe. FTC investigates three N.M. hospitals and their IPAs.
    Taylor M
    Mod Healthc; 2004 Apr; 34(16):12. PubMed ID: 15124438
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.